Compare WBI & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WBI | XERS |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | 540 | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | WBI | XERS |
|---|---|---|
| Price | $27.39 | $6.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $28.25 | $10.83 |
| AVG Volume (30 Days) | 635.1K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $70.12 | $34.37 |
| Revenue Next Year | $17.89 | $22.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $18.64 | $4.30 |
| 52 Week High | $30.81 | $10.08 |
| Indicator | WBI | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 56.50 |
| Support Level | $24.72 | $6.26 |
| Resistance Level | $28.97 | $6.41 |
| Average True Range (ATR) | 1.15 | 0.26 |
| MACD | -0.13 | 0.04 |
| Stochastic Oscillator | 27.36 | 47.23 |
WaterBridge Infrastructure LLC is an integrated, pure-play water infrastructure company with operations predominantly in the Delaware Basin, the prolific oil and natural gas basin in North America. It operates in the produced water infrastructure network in the United States through which it provides water management solutions to oil and natural gas E&P companies under long-term contracts, which include gathering, transporting, recycling, and handling produced water. It also operates two energy waste management facilities for the disposal of non-hazardous waste resulting from oil and gas E&P activities, branded under Desert Environmental. The transportation, treatment, and handling of produced water are crucial to oil and natural gas production.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.